secwatch.observer — SEC 8-K summary
======================================

Issuer:     CalciMedica, Inc. (CALC)
CIK:        0001534133
Form:       8-K
Filed at:   2023-08-11T23:59:59+00:00
Accession:  0001193125-23-210794
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CalciMedica updates biz description with CARPO trial expansion, AKI plans, recasted financials
--------------------------------------------------------------------------------

- CARPO Phase 2b in AP+SIRS expanded to India; topline results expected first half 2024.
- CRSPA Phase 1/2 in pediatric AIPT completed first cohort; data publication expected Q4 2023.
- AKI plan: IND submission H2 2023; Phase 2 trial H1 2024 subject to additional funding.
- CARDEA trial showed 56% relative mortality reduction at 30 days (p=0.0165) in severe COVID-19 pneumonia.
- Audited recasted financial statements of Private CalciMedica as of Dec 31, 2022 and 2021 filed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1534133/000119312523210794/0001193125-23-210794-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1534133/000119312523210794/d441914d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-210794

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer